Akashi Investigating Duchenne Patient Death
This article was originally published in Scrip
Akashi Therapeutics Inc. said it was investigating whether there was a link between its experimental Duchenne muscular dystrophy (DMD) therapy HT-100 and the death of a patient who had been participating in the firm's HALO trial when he experienced serious life-threatening health issues.
You may also be interested in...
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.